CA-ONCLUSIVE
5.1.2022 16:10:12 CET | Business Wire | Press release
Today, leading technology investor Symphony Technology Group “STG” completes its acquisition of Kantar ’s Reputation Intelligence business, and with it announces the additional purchases of PRgloo and Onclusive . Together the three businesses merge to create a new global media monitoring, measurement, and workflow management partner for PR and communications.
The new standalone company will operate under the name ‘Onclusive’ reflecting the inclusive and scalable nature of its newly combined offer and its commitment to accelerating investment in tech-powered platforms and solutions.
The company builds on the consultative strengths and scale of Europe’s largest media monitoring and analysis provider, Kantar Reputation Intelligence; UK-based PRgloo’s industry-leading media relations and workflow management platform and US-based Onclusive’s AI technology and data science.
Commenting on the new company, Chief Commercial Officer of the newly-formed Onclusive, Petra Masinova explained: “We’ve always admired each other’s strengths and we’ve increasingly teamed up on programmes to help solve clients’ needs. Today we accelerate our natural evolution to become one company, amplifying our strengths and supporting our clients with leading insights, technology and expertise together under one roof.”
Dan Beltramo, Chief Innovation Officer of the new Onclusive , also praised the union: “Onclusive is a technology and innovation pioneer in media monitoring and analytics while Kantar Reputation Intelligence is a leader in customer service with top-tier European coverage and market-leading insights capabilities. It brings us scale and ambition for global leadership.”
Samantha Deeks, VP Customer Experience at new Onclusive added: “Building on PRgloo’s customer-centric design approach, we’re delighted to work with like-minded industry leaders to build a scalable and agile business; one which actively listens and responds to the needs of its clients as they navigate an increasingly complex communications environment.”
Managing Director at STG, J.T. Treadwell , said: “Last year STG made clear its intention to create a market leading insights and software company through the proposed acquisition of Kantar Reputation Intelligence. Completing that acquisition is a major first step and the additional capabilities brought by Onclusive and PRgloo widen the scope of our commitment to providing best-in-class solutions for PR and Communications teams, both now and in the future.”
Onclusive will serve more than 9,000 clients, including many of the world’s biggest brands, across 130 markets. The company has over 1,100 employees based in the USA, UK, Ireland, France, Italy, Spain, Germany and Australia.
Onclusive North America Managing Director, Sean O’Neal , continued: “Our clients were our matchmakers – they told us they wanted one trusted partner to help them access and integrate our combined best-in-class services. We listened and from today Onclusive will help every client – from small enterprises to multi-national public and private organisations – shape, manage and evaluate their communications strategies.”
From today, clients can access the new Onclusive’s full range of services, supporting them at every stage of the communications cycle. Existing services continue uninterrupted.
About Onclusive
Onclusive is a global partner for PR and Communications success. We bring together Kantar Reputation Intelligence, the largest media monitoring and measurement service in Europe, with the best-in-class tools of PRgloo, and Onclusive’s own powerful AI and data science. Our technology, insights and expertise make sense of the fractured, fast-moving media world, helping you manage, monitor and measure your communications activity. Elevate your performance and prove and improve your value with Onclusive on your side.
About STG Partners
STG is a private equity partner to market leading companies in software, data analytics and software-enabled technology services sectors. The firm brings expertise, flexibility, and resources to build strategic value and unlock the potential of innovative companies. Partnering to build customer-centric, market leading portfolio companies, STG seeks to create sustainable foundations for growth that bring value to its companies. The firm is dedicated to transforming and building outstanding technology companies in partnership with leading management teams. STG and its predecessor, Symphony Technology Group (“Symphony”), have managed approximately $6 billion in total capital. For more information, please visit stgpartners.com
Kantar Reputation Intelligence – The leader in earned media tracking and measurement in Europe. Reputation Intelligence provides trusted insights on corporate, PR and brand coverage in 130+ markets to brands can understand and manage how audiences and influencers see them, globally and locally.
Onclusive – Empowers the world’s leading brands and agencies to modernize communications, increase performance and demonstrate value. The inventors of PR Attribution™ and Power of Voice™, Onclusive measures the true impact of earned, owned and social content on a company’s bottom line.
PRgloo – The complete media relations platform. PRgloo combines easy to use tools with exceptional analysis to make PR professionals’ lives easier by giving them the tools they need to do their jobs well.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom